148 related articles for article (PubMed ID: 2248280)
1. Octreotide: a long-acting somatostatin analog.
Brown NJ
Am J Med Sci; 1990 Oct; 300(4):267-73. PubMed ID: 2248280
[TBL] [Abstract][Full Text] [Related]
2. Octreotide, a new somatostatin analogue.
Katz MD; Erstad BL
Clin Pharm; 1989 Apr; 8(4):255-73. PubMed ID: 2653711
[TBL] [Abstract][Full Text] [Related]
3. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
Gorden P; Comi RJ; Maton PN; Go VL
Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
[TBL] [Abstract][Full Text] [Related]
4. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.
Battershill PE; Clissold SP
Drugs; 1989 Nov; 38(5):658-702. PubMed ID: 2689136
[TBL] [Abstract][Full Text] [Related]
5. Clinical review 23: The use of the long-acting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.
Wynick D; Bloom SR
J Clin Endocrinol Metab; 1991 Jul; 73(1):1-3. PubMed ID: 1646213
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].
Stöckmann F; Creutzfeldt W
Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248
[TBL] [Abstract][Full Text] [Related]
7. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
9. Debut of a somatostatin analog: octreotide in review.
Zindel LR
Conn Med; 1989 Dec; 53(12):741-4. PubMed ID: 2558839
[TBL] [Abstract][Full Text] [Related]
10. Potential gastrointestinal uses of somatostain and its synthetic analogue octreotide.
Grosman I; Simon D
Am J Gastroenterol; 1990 Sep; 85(9):1061-72. PubMed ID: 1975156
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analogue therapy in functioning neuroendocrine gut tumors.
Debas HT; Gittes G
Digestion; 1993; 54 Suppl 1():68-71. PubMed ID: 8359571
[TBL] [Abstract][Full Text] [Related]
12. Use of octreotide acetate for control of symptoms in patients with islet cell tumors.
Maton PN
World J Surg; 1993; 17(4):504-10. PubMed ID: 8395751
[TBL] [Abstract][Full Text] [Related]
13. Perioperative use of octreotide in gastrointestinal surgery.
Mulvihill SJ
Digestion; 1993; 54 Suppl 1():33-7. PubMed ID: 8359566
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours.
Chanson P; Timsit J; Harris AG
Clin Pharmacokinet; 1993 Nov; 25(5):375-91. PubMed ID: 8287633
[TBL] [Abstract][Full Text] [Related]
16. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
17. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
18. [Somatostatin analog (octreotide) in clinical use: current and potential indications].
Meier R; Dierdorf R; Gyr K
Schweiz Med Wochenschr; 1992 Jun; 122(25):957-68. PubMed ID: 1621078
[TBL] [Abstract][Full Text] [Related]
19. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge.
Pusceddu S; Prinzi N; Raimondi A; Corti F; Buzzoni R; Di Bartolomeo M; Seregni E; Maccauro M; Coppa J; Milione M; Mazzaferro V; de Braud F
Tumori; 2019 Apr; 105(2):113-120. PubMed ID: 29714658
[TBL] [Abstract][Full Text] [Related]
20. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
